# A Post-marketing, Observational, Retrospective Study to Assess the Safety of RefortrixTM (Tdap) When Administered During Pregnancy in a Maternal Immunization Program in Brazil.

> **NCT02757950** · — · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 2462 (actual)

## Conditions studied

- Diphtheria

## Interventions

- **BIOLOGICAL:** Combined diphtheria, tetanus and tricomponent acellular pertussis vaccine [Refortrix (Tdap)]

## Key facts

- **NCT ID:** NCT02757950
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-14
- **Primary completion:** 2017-05-31
- **Final completion:** 2017-05-31
- **Target enrollment:** 2462 (ACTUAL)
- **Last updated:** 2019-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02757950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02757950, "A Post-marketing, Observational, Retrospective Study to Assess the Safety of RefortrixTM (Tdap) When Administered During Pregnancy in a Maternal Immunization Program in Brazil.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02757950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*